{
    "id": "0596",
    "question": "Six hours after birth, a newborn boy is evaluated for tachypnea. He was delivered at 41 weeks' gestation via Caesarian section and the amniotic fluid was meconium-stained. His respiratory rate is 75/min. Physical examination shows increased work of breathing. X-rays of the abdomen and chest show no abnormalities. Echocardiography shows elevated pulmonary artery pressure. He is started on an inhaled medication that increases smooth muscle cGMP, and there is immediate improvement in his tachypnea and oxygenation status. Three hours later, the newborn is tachypneic and there is blue-grey discoloration of the lips, fingers, and toes. Which of the following is the most likely cause of this infant's cyanosis?",
    "options": {
        "A": "Increase in concentration of serum myoglobin",
        "B": "Closure of the ductus arteriosus",
        "C": "Oxidization of Fe2+ to Fe3+",
        "D": "Allosteric alteration of heme groups"
    },
    "answer": "C",
    "predict": "To approach this question, let's break down the key points from the scenario provided: 1. **Clinical Presentation**: The newborn presents with tachypnea and increased work of breathing six hours after birth, which indicates respiratory distress. The immediate improvement in symptoms after starting an inhaled medication that increases smooth muscle cGMP suggests that the medication is likely a nitric oxide (NO) donor, commonly used to treat patent ductus arteriosus (PDA) in preterm infants. 2. **Imaging and Lab Findings**: The X-rays show no abnormalities, and echocardiography indicates elevated pulmonary artery pressure. This points towards a condition affecting the ductus arteriosus, which is a normal fetal blood vessel that typically closes after birth. 3. **Cyanosis**: The appearance of blue-grey discoloration of the lips, fingers, and toes indicates cyanosis, which is a sign of inadequate oxygenation. 4. **Medication Side Effect**: The improvement followed by worsening of symptoms after the administration of a medication that increases smooth muscle cGMP suggests a side effect related to the medication's action on smooth muscle. Considering these points, let's evaluate the options: A. **Increase in concentration of serum myoglobin**: Myoglobin levels can cause cyanosis due to tissue hypoxia, but there's no direct connection between the medication and myoglobin levels in this scenario. B. **Closure of the ductus arteriosus**: This is a plausible explanation. The medication used initially was likely a nitric oxide donor, which would have kept the ductus arteriosus open. However, the side effect of this medication causing cyanosis suggests a rebound effect, which is characteristic of the closure of the ductus arteriosus. C. **Oxidation of Fe2+ to Fe3+**: This is not directly related to the clinical scenario and the medication's mechanism of action. D. **Allosteric alteration of heme groups**: While heme groups are crucial for oxygen transport, there's no direct link to the medication's action or the cyanosis in this scenario. Based on the analysis, the most likely cause of the infant's cyanosis is the closure of the ductus arteriosus, which is a known side effect of nitric oxide donors used to keep the ductus arteriosus open. **Answer Choice**: B",
    "snippets": [],
    "scores": [],
    "execution_time": 25.038506269454956
}